Scaling beyond limited early-stage momentum often calls for a disciplined corporate turnaround strategy. Jake Burlet outlines the practical steps CanBiocin took to shift from grant-to-grant R&D survival to a profitable growing enterprise through securing strategic investment.

Commercialising a new category of care requires more than product innovation. Rebecca Windsor, Director of Veterinary Affairs at Gallant, shares how education and developing trusted continuing education platforms have been central to preparing veterinarians for the clinical adoption of regenerative medicine.

Evolving pet owner expectations demand new models of engagement. Susan Groeneveld shares how Sylvester.AI is pioneering direct-to-consumer pathways to connect with owners, strengthen veterinary partnerships, and unlock commercial scale. 

Securing non-dilutive capital can be the key to bridging the gap between research and commercial reality for agtech startups. Matt Dobbs shares how AgSenze leveraged grant programmes including Innovate UK and EU Horizon to de-risk R&D, unlock private investment, and provide a launchpad of scaling HerdVision.

Advancing a new therapeutic class to market requires a balance of strong science, solid IP protection, and a regulatory path that supports early access. Hunter Land (CEO) shares how Lupvindol is progressing its CBD–corticosteroid combinations for canine IBD and equine osteoarthritis through compelling efficacy data, robust patent strategy, and the FDA’s expanded conditional approval route.

When innovation moves faster than policy, the path to market calls for creative approaches. Tammie Wahaus, CEO of ELIAS Animal Health, shares how her team advances pivotal trials, adapts human health technologies, and keeps development on track as regulatory expectations continue to evolve.